Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02735252 · ClinicalTrials.gov registry record · NA
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
A NA study of Prostate Cancer and Genitourinary Cancer, sponsored by University of California, San Francisco.
- Active
- Registry status
- NA
- Development phase
- 156
- Enrollment target
- 1
- Study location
NCT02735252: Active NA study of Prostate Cancer and Genitourinary Cancer, sponsored by University of California, San Francisco.
NCT02735252 is a NA study of Prostate Cancer and Genitourinary Cancer that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 156 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02735252, a NA study of Prostate Cancer and Genitourinary Cancer, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 156 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma. Whenever possible, a new bone lesion or new/progressing soft tissue lesion will be chosen for biopsy as opposed to radiographically stable lesion. Patients will be enrolled in into one of several parallel cohorts based upon disease status or type and the planned systemic therapy following baseline tumor biopsy: (A) Androgen signaling inhibition, (B) Immunotherapy, (C) Radiotherapy, (D) Targeted Therapy/Investigational therapeutic, (E) DNA damage response pathway, (F) Aggressive variant disease, (G1) Castration-sensitive ADT naïve and ADT \< 3 months), or (G2) Castration-sensitive pre-treated with sub-optimal PSA nadir \>0.2 ng/ml, (R) metastatic renal cell carcinoma and metastatic and (U) urothelial carcinoma.
Primary Outcome
Using PARADIGM and DiPSC tools, the investigators will discover genetic expression and clinical factors that are predictive of treatment benefit within each treatment cohort using correlative analysis.
Conditions Studied
Interventions
- OTHER Systemic therapy
- DEVICE StrataNGS
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2016-05-25 |
| Est. Completion | 2027-03-31 |
| Phase | NA |
What the registry record for NCT02735252 still lists
NCT02735252 is an interventional study that assigns participants to a tested intervention. The registered 156 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (74% lower).
The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Systemic therapy is the first listed.
NCT02735252 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02735252 about?
NCT02735252 is a clinical study titled "PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer". This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma. Whenever possible, a new bone lesion or new/progressing soft tissue lesion will be chosen for bio...
What is the current status of trial NCT02735252?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 156 participants. The study started on 2016-05-25. Estimated completion is 2027-03-31.
What conditions does trial NCT02735252 study?
This clinical trial studies the following conditions: Prostate Cancer, Genitourinary Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma.
What interventions are being tested in trial NCT02735252?
The interventions under investigation include: Systemic therapy (OTHER), StrataNGS (DEVICE).
Who is sponsoring clinical trial NCT02735252?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02735252 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02735252's enrollment target sits among peer trials
156 257th of 735 higher than 479 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03082755 · 156 participants · Phase 4
Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease
- NCT04047628 · 156 participants · Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- NCT04166877 · 156 participants · Phase 4
Magnesium Infusion for Pain Management in Critically Ill Trauma Patients
- NCT04533464 · 156 participants · Phase 2
MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI